Updated:
FibroBiologics, Inc.
Public biotech firm focused on fibroblast-based therapies for chronic disease, with lead program in intervertebral disc degeneration.
FibroBiologics, Inc.
FibroBiologics, Inc. is a clinical-stage biotechnology company that develops therapies using fibroblasts, a cell type central to tissue repair and fibrosis. The firm's core technology involves reprogramming these cells to treat chronic conditions such as degenerative disc disease and cancer. Its lead candidate targets intervertebral disc degeneration, a condition affecting millions annually. The company was founded by researchers with expertise in cell biology and holds patents covering methods to isolate and modulate fibroblast populations for therapeutic use. Its pipeline spans indications in orthopedics, oncology, and wound healing. The firm's strategy relies on proprietary fibroblast lines and intellectual property around cell-based platforms. It engages in preclinical studies and early-phase clinical trials conducted at academic medical centers. Public filings and press releases describe research collaborations with institutions studying disc degeneration and fibrosis. Geographic footprint is concentrated in the United States, with operations in Texas and other locations. The pipeline includes multiple preclinical programs beyond the lead disc therapy, covering fibrosis in other organs and potential anti-cancer applications. FibroBiologics is structured as a publicly traded corporation, listed on a US stock exchange. Team size and investor base are not publicly detailed in available sources. The firm's financials, including cash position and burn rate, are disclosed in SEC filings, but AUM or committed capital is not applicable as it is not an asset manager. No adjacent philanthropic or operating-company vehicles have been identified. The company's structural differentiator lies in its exclusive focus on fibroblast biology, a niche within cell therapy. Most competitors target stem cells or immune cells; FibroBiologics instead aims to harness the regenerative and fibrotic properties of fibroblasts. This specialization may reduce competition but carries higher technical risk. The firm's governance is that of a public biotech, with a board and management team accountable to shareholders.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What diseases does FibroBiologics target with its fibroblast therapies?
The firm targets intervertebral disc degeneration, as well as other fibrotic conditions and cancer. Its lead candidate addresses chronic low back pain from disc damage. Preclinical programs cover liver fibrosis and other tissue scarring indications. This focus is based on the role of fibroblasts in both repair and pathological fibrosis (per public filings).
Is FibroBiologics a family office or an asset manager?
No. FibroBiologics is a public biotechnology company, not a family office. It does not manage third-party capital or allocate to other funds. Any investment in the firm is through public equity markets.
How does FibroBiologics differentiate itself from other cell therapy companies?
Unlike most cell therapy firms that focus on stem cells or immune cells, FibroBiologics specifically engineers fibroblasts. This approach targets a distinct biological mechanism. The company holds patents around fibroblast isolation, modulation, and delivery (per its public filings).
What stage of clinical development is FibroBiologics in?
The firm is primarily preclinical and early clinical. Its lead program for intervertebral disc degeneration has progressed to Phase 1/2 trials. Other programs remain in preclinical validation. Public disclosures indicate ongoing safety and efficacy studies.
Where is FibroBiologics headquartered?
The firm is based in Texas, USA, according to public records. No additional offices have been publicly identified.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: